A retrospective study analysing association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
Latest Information Update: 04 Mar 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 06 Jul 2020 New trial record
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II